High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1

Journal of Virology

Volumn 74, Issue 2, 2000, Pages 1023-1028

  Imamichi, Tomozumi ^a   Sinha, Tanima ^a   Imamichi, Hiromi ^a   Zhang, Yi Ming ^a   Metcalf, Julie A ^b   Falloon, Judith ^b   Lane, H Clifford ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CODON; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GENE DELETION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0033986107     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.2.1023-1028.2000     Document Type: Article

References (53)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. AIDS Clinical Trials Group. 1997. Virology manual for HIV laboratories. [Online.] Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md. http://www.niaid.nih.gov./daids/vir_manual.
3. Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamedi-Sangsari, and J. Vila. 1995. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:36-40.
4. Boyer, P. L., M. J. Currens, J. B. McMahon, M. R. Boyd, and S. H. Hughes. 1993. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:2412-2420.
5. Byrnes, V. W., E. A. Emini, W. A. Schleif, J. H. Condra, C. L. Schneider, W. J. Long, J. A. Wolfgang, D. J. Graham, L. Gotlib, A. J. Schlabach, B. S. Wolanski, O. M. Blahy, J. C. Quintero, A. Rhodes, E. Roth, D. L. Titus, and V. V. Sardana. 1994. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 38:1404-1407.
6. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
7. Daluge, S. M., S. S. Good, M. B. Faletto, M. T. Martin, W. H. Miller, D. R. Averett, M. H. St. Clair, L. R. Boone, M. Tisdale, and J. E. Reardon. 1995. 1592U89 succinate - a potent, selective anti-HIV carhocyclic nucleoside. Antivir. Res. 26:A228.
8. De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903.
9. Dewar, R. L., H. C. Highbarger, M. D. Sarmiento, J. A. Todd, M. B. Vasudevachari, R. T. Davey, Jr., J. A. Kovacs, N. P. Salzman, H. C. Lane, and M. S. Urdea. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
10. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993 U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Anti-microb. Agents Chemother. 37:1127-1131.
11. Egger, M., B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, M. Rickenbach, R. Malinverni, P. Vernazza, and M. Battegay. 1997. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br. Med. J. 315:1194-1199.
12. Emini, E. A. 1996. Non-nucleoside reverse transcriptase inhibitors - mechanisms, p. 225-240. In D. D. Richman (ed.). Antiviral drug resistance. John Wiley and Sons, Ltd., New York, N.Y.
13. Fatkenheuer, G., A. Theisen, J. Rockstroh, T. Grabow, C. Wicke, K. Becker, U. Wieland, H. Pfister, M. Reiser, P. Hegener, C. Franzen, A. Schwenk, and B. Salzberger. 1997. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11:F113-F1 16.
14. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
15. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
16. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, W. A. Schleif, K. F. Freund. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88:6863-6867.
17. Haertle, T., C. J. Carrera, D. B. Wasson, L. C. Sowers, D. D. Richman, and D. A. Carson. 1988. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263: 5870-5875.
18. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-[II/ LAV in HTLV-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
19. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Nájera, A. Kohli, and B. A. Larder. 1976. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
20. Hirschel, B., and P. Francioli. 1998. Progress and problems in the fight against AIDS. N. Engl. J. Med 338:906-908.
21. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:8010-8018.
22. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implication for drug resistance. Science 282:1669-1675.
23. Kashman, Y., K. R. Gustafson, R. W. Fuller, J. H. Cardellina II, J. B. McMahon, M. J. Currens, R. W. Buckheit, Jr., S. H. Hughes, G. M. Cragg, and M. R. Boyd. 1993. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree. Calophyllum lanigerum. J. Med. Chem. 35:2735-2743.
24. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
25. Kleim, J. P., M. Rosner, I. Winkler, A. Paessens, R. Kirsch, V. Hsiou, E. Arnold, and G. Riess. 1996. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA 93:34-38.
26. Koup, R. A., V. J. Merluzzi, K. D. Margrave, J. Adams, K. Grozinger, R. J. Eckner, and J. L. Sullivan. 1991. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J. Infect. Dis. 163:966-970.
27. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
28. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
29. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
30. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
31. Larder, B. A., A. Kohli, S. Bloor, S. D. Kemp, P. R. Harrigan, R. T. Schooley, J. M. A. Lange, K. N. Pennington, M. H. St. Clair, and the Protocol 34,225-02 Collaborative Group. 1996. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J. Virol. 70:5922-5929.
32. Lin, T. S., R. F. Schinazi, and W. H. Prusoff. 1987. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36:2713-2718.
33. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
34. Mayer, D. L., F. E. McCutchan, E. E. Sanders-Buell, L. I. Merritt, S. Dilworth, A. H. Fowlwe, C. A. Marks, N. M. Ruiz, D. D. Richman, C. R. Roberts, and D. S. Burke. 1992. Characterization of HIV isolates arising after prolonged zidovudine therapy. AIDS 5:749-759.
35. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411-1413.
36. Mouton, Y., S. Alfandari, M. Valette, F. Cartier, P. Dellamonica, G. Humbert, J. M. Lang, P. Massip, D. Mechali, P. Leclercq, J. Modai, and H. Portier, 1997. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 11:F101-F105.
37. Myers, G., B. T. Korber, S. Wain-Hobson, R. Smith, and G. N. Pavlakas. 1995. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. [Online.] Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, N.Mex. http:// hiv-web.lanl.gov.
38. Natarajan, V., M. Bosche, J. A. Metcalf, D. J. Ward, H. C. Lane, and J. A. Kovacs. 1999. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 353:119-120.
39. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. D. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
40. Pauwels, R., J. Balzarini, D. Schols, M. Baba, J. Desmyter, I. Rosenberg, A. Holy, and E. De Clercq. 1988. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1025-1030.
41. Perii, L., and A. Telenti. 1998. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280:1871-1873.
42. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrwt, J. S. Mills, K. E. B. Oarkes, S. Redshaw, A. J. Ritchie, K. L. Taylor, G. T. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
43. Rook, R., M. Tremblay, H. Soudeyns, L. DeStephano, X. J. Yao, M. Fanning, J. S. Montaner, M. O'Shaughnessy, K. Gelmon, C. Tsoukas, J. Gill, J. Ruedy, and M. A. Wainberg. 1989. Isolation of drug-resistance variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3:411-415.
44. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 5:2-14.
45. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chockekuchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxy-nucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
46. Soudeyns, H., X.-J. Yao, Q. Gao, B. Belleau, J.-L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1386-1390.
47. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three dimensional structure of HIV-1 RT. J. Mol. Biol. 243:369-387.
48. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Ruth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
49. Vandamme, A. M., K. Van Laethem, K. Van Vaerenbergh, and E. De Clercq. 1999. Anti-HIV virus combination therapy and resistance management. Int. Antivir. News 6:182-187.
50. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102: 1769-1775.
51. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
52. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, T.-W. Chen, W. A. Schleif, V. V. Sordana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.
53. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.